0 Items
Select Page

Epstein Barr Virus

The Epstein–Barr virus (EBV) is one of the most commonly found viruses in humans and is best known for causing infectious mononucleosis (glandular fever). EBV is also associated with particular forms of cancer, including Hodgkin’s lymphoma, Burkitt’s lymphoma, gastric cancer and nasopharyngeal carcinoma. About 200,000 cancer cases per year are thought to be attributable to EBV.

The Native Antigen Company have developed recombinant antigens for use in EBV research and assay development.

Epstein Barr Virus Background

Epstein Barr Virus (EBV) is a double-stranded DNA, enveloped virus, with a large genome encoding 200 proteins. Epstein Barr virus, also known as Herpes virus 4 (HHV4), belongs to the gammaherpesvirinae subgroup of the Herpesvirus family.

EBV is widely distributed and is estimated to affect around 90% of the human population. In developing countries, most children contract EBV infection at an early age. In developed countries, primary EBV infection is more common in adolescents and adults. The Epstein-Barr virus is commonly spread from human-to-human through saliva and other body fluids (CDC).

In most cases, EBV Infection is asymptomatic, but some individuals develop infectious mononucleosis, a condition that is generally self-limiting but can cause prolonged fatigue lasting for several months. After primary EBV infection, the virus remains latent and can re-activate under certain circumstances. In immunocompromised patients, EBV infection is associated with various malignancies, autoimmune disease and other chronic and acute illnesses.

Epstein-Barr virus primarily targets B-lymphocytes but is also reported to infect epithelial cells, T-cells, natural killer cells, smooth muscle cells and monocytes (Hutt-Fletcher, L.M.).

Epstein Barr Virus Antigens

The Native Antigen Company has developed and produces recombinant Epstein Barr Virus gp125 antigens using our proprietary mammalian expression system. These antigens are suitable for research and development into Epstein-Barr virus biology and in the development of immunoassays.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Using Adenoviruses to Fight Cancer

In the second of a 2-part series, we discuss how adenoviruses are being developed to treat cancer and some of the hurdles these platforms face from our own immune systems. Curing cancer is one of the biggest challenges of the 21st century. Our knowledge of cancer’s...

New Immunofluorescence Data for our CMV, Yellow Fever and Ebola Antibodies

In September 2018 The Native Antigen Company and Virology Research Services (VRS) were awarded the Medical Research Council (Proximity to Discovery Award for Knowledge Exchange) to test a large panel of our viral antibodies in immunofluorescence applications. This...

Why are ticks such good vectors of pathogens?

In this blog, Professor Patricia Nuttall discusses what makes ticks such effective vectors of pathogens and how we might prevent the spread of tick-borne diseases. About Patrica Nuttall Pat Nuttall is Emeritus Professor of Arbovirology in the Department of Zoology,...

Dengue in 2019

What's going on with dengue? Dengue virus (DENV) has been in the news a lot recently. The number of reported cases continues to climb year-on-year and 2019 has been especially bad. Rio de Janeiro has seen a 45% increase in dengue cases in the first two months of 2019...

Zika Prevalence in Suriname – an insight into assay cross-reactivity

A recent study published by Langerak et al tested for the seroprevalence of Zika virus in Suriname populations and evaluated the comparative effectiveness of using a commercial ELISA and a standard Virus Neutralisation Assay. Here we discuss the study, its results,...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

3 + 14 =

Live Customer Feedback